Encision AI Stock Analysis
Want to see ECIA full AI Analyst Report?
Encision (ECIA) AI Stock Analysis
Encision
(Other OTC:ECIA)
The overall score is at the minimum of 37, reflecting severe fundamental and technical distress. The company is unprofitable with declining revenue, negative cash flow, and a debt-laden balance sheet. The stock is in a deep downtrend with no valuation support, presenting extreme risk.
Encision (ECIA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $221.12K
- Dividend Yield
- ―
- Average Volume (3M)
- 13.40K
- Price to Earnings (P/E)
- -13.1
- Beta (1Y)
- 26.75
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 23
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Encision Business Overview & Revenue Model
Company Description
Encision Inc. (ECIA), established in 1991 and headquartered in Boulder, Colorado, operates as a medical device firm specializing in the development, manufacturing, and commercialization of proprietary surgical instruments for the U.S. market. The com...
How the Company Makes Money
Encision’s primary revenue source was the sale of medical device products incorporating its Active Electrode Monitoring (AEM) technology, including AEM-enabled laparoscopic instruments and associated components used in electrosurgery. Beyond product...
Encision Financial Statement Overview
Summary
Financial health is critically weak. Revenue is declining, operating losses are persistent, equity is eroding, and cash flow is negative. The debt-to-equity ratio exceeds 1.0, signaling high solvency risk.
Income Statement
22NegativeBalance Sheet
28NegativeCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Jun 2025 | Jun 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.39M | 5.78M | 6.56M | 6.59M | 7.35M | 7.67M |
| Gross Profit | 1.12M | 2.71M | 3.51M | 3.14M | 4.03M | 3.79M |
| EBITDA | 53.67K | -542.60K | -95.08K | -544.20K | -217.51K | 55.10K |
| Net Income | -16.94K | -719.08K | -220.20K | -691.78K | -366.00K | 463.34K |
Balance Sheet | ||||||
| Total Assets | 3.45M | 3.70M | 3.67M | 3.81M | 4.13M | 4.79M |
| Cash, Cash Equivalents and Short-Term Investments | 275.43K | 245.11K | 257.43K | 42.51K | 189.00K | 950.00K |
| Total Debt | 1.42M | 1.70M | 1.31M | 1.33M | 1.08M | 1.15M |
| Total Liabilities | 1.96M | 2.27M | 2.02M | 1.98M | 1.64M | 2.05M |
| Stockholders Equity | 1.50M | 1.43M | 1.65M | 1.83M | 2.50M | 2.75M |
Cash Flow | ||||||
| Free Cash Flow | 29.69K | -427.64K | -134.97K | 107.57K | -1.04M | -480.00K |
| Operating Cash Flow | 29.69K | -384.42K | -54.95K | 144.39K | -861.00K | -444.00K |
| Investing Cash Flow | -4,712 | -45.62K | -80.03K | -36.82K | -183.00K | -36.00K |
| Financing Cash Flow | 5,342 | 417.72K | 349.90K | -254.02K | 284.00K | -44.00K |
Encision Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ECIA, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 41.91 is Neutral, neither overbought nor oversold. The STOCH value of -3.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ECIA.
Encision Risk Analysis
Encision disclosed 14 risk factors in its most recent earnings report. Encision reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksEncision Peers Comparison
Overall Rating
WOK43Neutral
LUCY42Neutral
GCTK38Underperform- ECIA37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| WOK | 43Neutral | $5.58M | -0.01 | -18.55% | ― | ― | ― |
| LUCY | 42Neutral | $7.03M | -0.65 | -102.66% | ― | 56.89% | 52.61% |
| GCTK | 38Underperform | $284.19K | -0.00 | -2135.52% | ― | ― | 99.51% |
| ECIA | 37Underperform | $221.12K | -13.10 | -1.15% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ECIA | Encision Inc. | 0.01 | -0.23 | -94.58% | |
| GCTK | Glucotrack, Inc. | 0.22 | -155.78 | -99.86% | |
| LUCY | Innovative Eyewear, Inc. | 0.81 | -0.80 | -49.81% | |
| WOK | WORK Medical Technology Group LTD | 1.20 | -40898.80 | -100.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026